THE DEAL, AT A GLANCE
From the announcementJasper Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedJasper Therapeutics raised $75M Series BFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersJasper Therapeutics is financing JSP191 as a targeted antibody conditioning approach intended to reduce reliance on toxic chemotherapy before stem cell transplant.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Jasper Therapeutics · Financing Record
Explore source-linked visual explanations for Jasper Therapeutics. Unsupported claims are withheld while source review continues.
Record 1468 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →